Reviews for Primary Care - Fall 2007 - (Page 39) The Renin-Angiotensin System and Cardiovascular Diseases 24. 25. 26. 27. 28. 29. 30. 31. Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-1226. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. Dahlof B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997;10:705-713. ALLHAT Investigators. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting— enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031. Vander AJ, Greelhoed GW. Inhibition of renin secretion by Ang II. Proc Soc Exp Biol Med. 1965;120:339-403. Skeggs LT, Kahn JR, Lentz KE, Shumway NP. Preparation, purification and amino acid sequence 32. 33. 34. 35. 36. 37. 38. 39. of a polypeptide renin substrate. J Exp Med. 1957;106:439-453. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensinconverting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004; 109:2492-2499. Biollaz J, Brunner HR, Gavras I, et al. Antihypertensive therapy with MK 421: angiotensin II–renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4:966-972. van den Meiracker AH, Man in ’t Veld AJ, Admiraal PJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens. 1992;10:803-812. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21: 53-57. Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68:11901198. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361: 117-124. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771. Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 2005;16:592-599. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. Wood JM, Cumin F, Maibaum J. Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol Ther. 1994;61:325-344. Wood JM, Maibaum J, Rahuel J, et al. Structurebased design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698-705. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002; 39:E1-E8. Stanton A, Jensen C, Nussberger J, O’Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42:1137-1143. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012-1018. Oh B-H, Chung J, Khan M, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in patients with hypertension. J Am Coll Cardiol. 2006;47(4 suppl A):1027. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126-3133. Giles TD, Berk BC, Black HR, et al. Expanding the definition and classification of hypertension. J Clin Hypertens. 2005;7:505-512. Julius S, Nesbitt S, Egan B, et al. Trial of preventing hypertension: design and 2-year progress report. Hypertension. 2004;44:146-151. Nesbitt SD, Julius S, Leonard D, et al. Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY study. Am J Hypertens. 2005;18:980-985. VOL. 1 NO. 1 2007 REVIEWS FOR PRIMARY CARE 39
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.